Collective Family Office LLC Purchases Shares of 2,340 Boston Scientific Co. (NYSE:BSX)

Collective Family Office LLC purchased a new stake in shares of Boston Scientific Co. (NYSE:BSX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,340 shares of the medical equipment provider’s stock, valued at approximately $209,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Bank of New Hampshire increased its position in Boston Scientific by 14.8% in the fourth quarter. Bank of New Hampshire now owns 2,565 shares of the medical equipment provider’s stock worth $229,000 after purchasing an additional 330 shares during the period. CWA Asset Management Group LLC raised its stake in shares of Boston Scientific by 4.2% during the fourth quarter. CWA Asset Management Group LLC now owns 8,281 shares of the medical equipment provider’s stock worth $740,000 after buying an additional 336 shares during the last quarter. Nordea Investment Management AB raised its stake in Boston Scientific by 6.7% during the 4th quarter. Nordea Investment Management AB now owns 119,535 shares of the medical equipment provider’s stock worth $10,713,000 after buying an additional 7,540 shares during the period. Everence Capital Management Inc. grew its stake in Boston Scientific by 15.8% in the fourth quarter. Everence Capital Management Inc. now owns 49,660 shares of the medical equipment provider’s stock valued at $4,436,000 after acquiring an additional 6,770 shares during the period. Finally, GAMMA Investing LLC increased its holdings in shares of Boston Scientific by 25.1% in the fourth quarter. GAMMA Investing LLC now owns 21,809 shares of the medical equipment provider’s stock worth $1,948,000 after acquiring an additional 4,377 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 4.6 %

BSX stock traded up $4.22 during trading on Wednesday, reaching $96.21. 5,549,844 shares of the stock were exchanged, compared to its average volume of 4,392,125. The firm has a market cap of $141.80 billion, a P/E ratio of 79.51, a price-to-earnings-growth ratio of 2.67 and a beta of 0.80. Boston Scientific Co. has a twelve month low of $58.09 and a twelve month high of $96.91. The firm’s 50 day moving average is $89.25 and its 200 day moving average is $83.50. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The business had revenue of $4.21 billion during the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. Boston Scientific’s quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.50 EPS. As a group, research analysts forecast that Boston Scientific Co. will post 2.46 EPS for the current year.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now directly owns 978 shares of the company’s stock, valued at approximately $87,306.06. This represents a 93.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP John Bradley Sorenson sold 4,119 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the transaction, the executive vice president now directly owns 35,319 shares of the company’s stock, valued at approximately $3,179,416.38. This represents a 10.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,989 shares of company stock worth $2,702,261 in the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

BSX has been the topic of several recent analyst reports. Canaccord Genuity Group lifted their price objective on Boston Scientific from $98.00 to $101.00 and gave the company a “buy” rating in a report on Monday, December 9th. Citigroup upped their price objective on Boston Scientific from $98.00 to $107.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. lifted their target price on Boston Scientific from $100.00 to $110.00 and gave the company an “overweight” rating in a research report on Monday, December 16th. Bank of America boosted their price objective on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. Finally, Mizuho raised their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $95.96.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.